Review
Clinical Neurology
Tyler Ellis Smith, Ilya Kister
Summary: This review provides a systematic framework for infectious risk mitigation strategies relevant to the newer, higher-efficacy disease-modifying therapies for multiple sclerosis. The strategies include screening, vaccinations, antibiotic prophylaxis, monitoring, dose adjustment, and behavioral modifications to reduce the risk of infections. Specific recommendations are also discussed for infections such as hepatitis B, herpetic infections, progressive multifocal leukoencephalopathy, tuberculosis, and COVID-19 vaccinations for patients on DMTs.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
(2021)
Article
Pharmacology & Pharmacy
Maria Antonietta Barbieri, Emanuela Elisa Sorbara, Alessandro Battaglia, Giuseppe Cicala, Vincenzo Rizzo, Edoardo Spina, Paola Maria Cutroneo
Summary: This study analyzed adverse drug reactions (ADRs) related to drugs used in the treatment of multiple sclerosis (MS). The majority of reported ADRs were not serious and were more commonly reported by female patients aged 18-65. The most common ADRs were related to general body and administration site conditions. Some unexpected ADRs, including dyslipidemia, abortion, alopecia, vitamin D deficiency, breast cancer, and hypothyroidism, were found. Further research is needed to increase awareness of the safety profiles of new drugs.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Clinical Neurology
Francesca Washington, Dawn Langdon
Summary: Research shows that patients with multiple sclerosis often struggle with treatment adherence, influenced by factors such as age, gender, emotions, cognition, and treatment satisfaction. Targeted patient support programs should be developed to improve treatment compliance.
JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Hans-Peter Hartung, Sven G. Meuth, Deborah M. Miller, Giancarlo Comi
Summary: The review assesses the reasons for considering discontinuation of disease-modifying therapies in MS patients, finding that stopping treatment may be feasible for older individuals with stable disease. Prognostic factors have been identified, and several clinical scenarios provide rationale for stopping treatment. Recent evidence allows for a more precise weighing of risks against benefits.
CURRENT OPINION IN NEUROLOGY
(2021)
Review
Medicine, General & Internal
Carmen Adella Sirbu, Raluca Ivan, Titus Mihai Vasile, Lucian George Eftimie, Daniel Octavian Costache
Summary: This article emphasizes the adverse cutaneous reactions to monoclonal antibodies used in the treatment of multiple sclerosis, based on two cases. The clinicians should be aware of the existence of these reactions and adjust the therapy accordingly.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Clinical Neurology
W. Daniel Chapman, Megan C. Herink, Michelle H. Cameron, Dennis Bourdette
Summary: Polypharmacy, the use of multiple medications, is common in people with multiple sclerosis and can lead to negative outcomes. This review examines the prevalence and risks associated with polypharmacy in multiple sclerosis patients, and provides strategies to identify and mitigate inappropriate polypharmacy.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
(2023)
Article
Clinical Neurology
Massimo Filippi, Maria Pia Amato, Diego Centonze, Paolo Gallo, Claudio Gasperini, Matilde Inglese, Francesco Patti, Carlo Pozzilli, Paolo Preziosa, Maria Trojano
Summary: Early intervention with high-efficacy disease-modifying therapies (HE-DMTs) can significantly reduce inflammation and disease progression in patients with multiple sclerosis (MS), with acceptable long-term safety risks.
JOURNAL OF NEUROLOGY
(2022)
Article
Medicine, General & Internal
Yan-zhong Han, Yu-ming Guo, Peng Xiong, Fei-lin Ge, Jing Jing, Ming Niu, Xu Zhao, Zhao-fang Bai, Hai-bo Song, Xiao-he Xiao, Jia-bo Wang
Summary: This study found that the aging population is more susceptible to liver-related ADRs, with the relative risk increasing exponentially with age. It is important to address risk management for older adults when using drugs with a high correlation to the risk of ADRs.
FRONTIERS IN MEDICINE
(2022)
Review
Clinical Neurology
Susana Otero-Romero, Alberto Ascherio, Christine Lebrun-Frenay
Summary: New evidence supports the lack of causal link between MS and vaccination, with consensus statements emphasizing the importance of starting vaccination early. Timing adjustments for vaccine administration are necessary to ensure safety and optimize vaccine responses in light of potential interference from DMDs. Patients on B-cell depleting therapies like Ocrelizumab are at risk of reduced immunogenicity to vaccines, highlighting the implications for upcoming SARS-CoV-2 vaccination.
CURRENT OPINION IN NEUROLOGY
(2021)
Article
Rehabilitation
Meheroz H. Rabadi, Kimberly Just, Chao Xu
Summary: This study aimed to determine the association between adherence to disease-modifying therapies (DMTs) and employment in patients with multiple sclerosis (MS). The results showed that patients who adhered to DMTs were more likely to be in paid employment, providing motivation for encouraging adherence.
DISABILITY AND REHABILITATION
(2022)
Article
Clinical Neurology
Berenice A. Silva, Edgar Carnero Contentti, Jefferson Becker, Jose Carranza, Patricio E. Correa-Diaz, Lorna Galleguillos Goiry, Orlando Garcea, Fernando Gracia, Fernando Hamuy, Miguel Angel Macias, Carlos Navas, Sebastian Nunez, Juan Rojas, Mauricio F. Farez, Ricardo Alonso, Pablo Lopez
Summary: This study provides consensus recommendations on the risk of infections in patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) in Latin America. The recommendations are based on relevant published evidence and expert opinion, covering areas such as baseline infection disease and vaccination status, opportunistic infections, progressive multifocal leukoencephalopathy, genitourinary system infections, respiratory tract infections, digestive system infections, other local infections, and COVID-19. These recommendations aim to optimize the care, management, and treatment of MS patients in Latin America, leading to better outcomes.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Ronen Spierer, Idit Lavi, Sivan Bloch, Marianna Mazar, Daniel Golan
Summary: This study aimed to explore the association between different disease-modifying therapies (DMTs) and the risk of breakthrough COVID-19. The results showed that vaccination effectively protects people with multiple sclerosis (pwMS) from COVID-19, but high-efficacy DMTs may increase the risk of breakthrough infection, although COVID-19 after vaccination is usually mild.
JOURNAL OF NEUROLOGY
(2023)
Article
Pharmacology & Pharmacy
Vasileios-Periklis Stamatellos, Spyridon Siafis, Georgios Papazisis
Summary: The study found no safety signal for increased cancer risk among approved disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS). However, a potential safety signal was detected in the sensitivity analysis for interferon beta-1a and alemtuzumab, warranting further evaluation with more robust evidence.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Review
Chemistry, Medicinal
Malene J. Petersen, Sofie O. Bergien, Dan Staerk
Summary: This systematic review provides information on the safety of simultaneous use of conventional MS-drugs and herbal drugs frequently used by PwMS. Findings suggest not exceeding recommended doses of Panax ginseng and Ginkgo biloba, and the need for further research on interactions between certain herbal preparations and other medications.
PHYTOTHERAPY RESEARCH
(2021)
Article
Neurosciences
Eleonora Sgarlata, Clara Grazia Chisari, Simona Toscano, Chiara Finocchiaro, Salvatore Lo Fermo, Enrico Millefiorini, Francesco Patti
Summary: This study evaluated the effects of different disease-modifying therapies on the JCV index. The results showed that treatments with T and/or B cell depleting mechanisms significantly reduced the JCV index. These findings suggest potential new strategies for reducing the risk of PML.
CURRENT NEUROPHARMACOLOGY
(2022)
Editorial Material
Clinical Neurology
Daniel Ontaneda
MULTIPLE SCLEROSIS JOURNAL
(2017)
Article
Medicine, General & Internal
Daniel Ontaneda, Alan J. Thompson, Robert J. Fox, Jeffrey A. Cohen
Article
Clinical Neurology
Andrew J. Solomon, Richard Watts, Daniel Ontaneda, Martina Absinta, Pascal Sati, Daniel S. Reich
MULTIPLE SCLEROSIS JOURNAL
(2018)
Article
Clinical Neurology
Andrew J. Solomon, Richard Watts, Daniel Ontaneda, Martina Absinta, Pascal Sati, Daniel S. Reich
MULTIPLE SCLEROSIS JOURNAL
(2018)
Editorial Material
Clinical Neurology
Bryan S. Lee, Rebecca L. Achey, Gabrielle A. Yeaney, David S. Bosler, Zarmeneh Aly, Daniel Ontaneda, John Morren, Edward C. Benzel
Article
Clinical Neurology
J. D. Dworkin, P. Sati, A. Solomon, D. L. Pham, R. Watts, M. L. Martin, D. Ontaneda, M. K. Schindler, D. S. Reich, R. T. Shinohara
AMERICAN JOURNAL OF NEURORADIOLOGY
(2018)
Article
Clinical Neurology
Bruce D. Trapp, Megan Vignos, Jessica Dudman, Ansi Chang, Elizabeth Fisher, Susan M. Staugaitis, Harsha Battapady, Sverre Mork, Daniel Ontaneda, Stephen E. Jones, Robert J. Fox, Jacqueline Chen, Kunio Nakamura, Richard A. Rudick
Article
Medicine, General & Internal
R. J. Fox, C. S. Coffey, R. Conwit, M. E. Cudkowicz, T. Gleason, A. Goodman, E. C. Klawiter, K. Matsuda, M. McGovern, R. T. Naismith, A. Ashokkumar, J. Barnes, D. Ecklund, E. Klingner, M. Koepp, J. D. Long, S. Natarajan, B. Thornell, J. Yankey, R. A. Bermel, J. P. Debbins, X. Huang, P. Jagodnik, M. J. Lowe, K. Nakamura, S. Narayanan, K. E. Sakaie, B. Thoomukuntla, X. Zhou, S. Krieger, E. Alvarez, M. Apperson, K. Bashir, B. A. Cohen, P. K. Coyle, S. Delgado, L. D. Dewitt, A. Flores, B. S. Giesser, M. D. Goldman, B. Jubelt, N. Lava, S. G. Lynch, H. Moses, D. Ontaneda, J. S. Perumal, M. Racke, P. Repovic, C. S. Riley, C. Severson, S. Shinnar, V. Suski, B. Weinstock-Guttman, V. Yadav, A. Zabeti
NEW ENGLAND JOURNAL OF MEDICINE
(2018)
Editorial Material
Clinical Neurology
Gabrielle Macaron, Daniel Ontaneda
MULTIPLE SCLEROSIS JOURNAL
(2019)
Article
Clinical Neurology
Daniel Ontaneda, Jacqueline Nicholas, Matthew Carraro, Jia Zhou, Qiang Hou, Jaanai Babb, Katherine Riester, Jason P. Mendoza, Terrie Livingston, Mehul Jhaveri
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2019)
Editorial Material
Clinical Neurology
Marisa McGinley, Daniel Ontaneda
MULTIPLE SCLEROSIS JOURNAL
(2019)
Review
Clinical Neurology
Jiwon Oh, Daniel Ontaneda, Christina Azevedo, Eric C. Klawiter, Martina Absinta, Douglas L. Arnold, Rohit Bakshi, Peter A. Calabresi, Ciprian Crainiceanu, Blake Dewey, Leorah Freeman, Susan Gauthier, Roland Henry, Mathilde Inglese, Shannon Kolind, David K. B. Li, Caterina Mainero, Ravi S. Menon, Govind Nair, Sridar Narayanan, Flavia Nelson, Daniel Pelletier, Alexander Rauscher, William Rooney, Pascal Sati, Daniel Schwartz, Russell T. Shinohara, Ian Tagge, Anthony Traboulsee, Yi Wang, Youngjin Yoo, Tarek Yousry, Yunyan Zhang, Nancy L. Sicotte, Daniel S. Reich
Article
Clinical Neurology
Farren B. S. Briggs, Justin C. Yu, Mary F. Davis, Jinghong Jiangyang, Shannon Fu, Erica Parrotta, Douglas D. Gunzler, Daniel Ontaneda
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2019)
Article
Clinical Neurology
Brandi Vollmer, Daniel Ontaneda, Anasua Bandyopadhyay, Sam Cohn, Kavita Nair, Stefan Sillau, Robert A. Bermel, John R. Corboy, Roberti Fox, Timothy Vollmer, Jeffrey A. Cohen, Enrique Alvarez, Carrie M. Hersh
NEUROLOGY-CLINICAL PRACTICE
(2018)
Review
Clinical Neurology
Jenny J. Feng, Daniel Ontaneda
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE
(2017)